-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44

Benzinga·11/05/2026 17:31:03
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $46 to $44.